Citalopram as an adjuvant in schizophrenia: Further evidence for a serotonergic dimension in schizophrenia

International Clinical Psychopharmacology

Volumn 12, Issue 1, 1997, Pages 31-35

  Taiminen, T J ^a   Syvalahti E ^b   Saarijarvi S ^a   Niemi, H ^b   Lehto, H ^b   Ahola, V ^b   Salokangas, R K R ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Anxiety; Citalopram; Depression; Schizophrenia

Indexed keywords

CITALOPRAM; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ANXIETY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0030899569     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199701000-00004     Document Type: Article

References (30)

1. Addington D, Addington J and Maticka-Tyndale E (1993) Assessing depression in schizophrenia: the Galgary Depression Scale. British Journal of Psychiatry, 163 (suppl 22), 39-44.
2. Addington D, Addington J and Maticka-Tyndale E (1994) Specificity of the Calgary Depression Scale for schizophrenics. Schizophrenia Research, 11, 239-244.
3. Andreasen NC, Arndt S, Alliger R, Miller D and Flaum M (1995) Symptoms of schizophrenia: methods, meanings, and mechanisms. Archives of General Psychiatry, 52, 341-351.
4. Bartels SJ and Drake RE (1988) Depressive symptoms in schizophrenia: comprehensive differential diagnosis. Comprehensive Psychiatry, 29, 467-483.
5. Bland JM and Altman DG (1995) Multiple significance tests: the Bonferroni method. British Medical Journal, 310, 170.
6. Breier A, Schreiber JL, Dyer J and Pickar D (1991) National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Archives of General Psychiatry, 48, 239-246.
7. Caldwell CB and Gottesman II (1990) Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophrenia Bulletin, 16, 571-589.
8. Cooper SJ, Kelly CB and King DJ (1992) 5-Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behaviour in schizophrenia. Lancet, 340, 940-941.
9. Crow TJ (1980) Molecular pathology of schizophrenia: more than one process? British Medical Journal, 280, 66-68.
10. Dubovsky SL and Thomas M (1995) Serotonergic mechanisms and current and future psychiatric practice. Journal of Clinical Psychiatry, 56(suppl 2), 38-48.
11. Goff DC, Brotman AW, Waites M and McCormick S (1990) Trial of fluoxetine added to neuroleptics for treatmentresistant schizophrenic patients. American Journal of Psychiatry, 147, 492-494.
12. Goldman MB and Janacek HM (1990) Adjunctive fluoxetine improves global function in chronic schizophrenia. Journal of Neuropsychiatry, 2, 429-431.
13. Hamilton M (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278-296.
14. Kay SR, Opler LA and Fiszbein A (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
15. Kulhara P, Avasthi R, Chadda R, Chandiramani K, Mattoo SK, Kota SK and Joseph S (1989) Negative and depressive symptoms in schizophrenia. British Journal of Psychiatry, 154, 207-211.
16. Lindenmayer J-P, Bernstein-Hyman R and Grochowski S (1994) Five-factor model of schizophrenia: initial validation. Journal of Nervous and Mental Disease, 182, 631-638.
17. Lindenmayer J-P, Grochowski S and Hyman RB (1995) Five factor model of schizophrenia: replication across samples. Schizophrenia Research, 14, 229-234.
18. Loas G, Byer P and Legrand A (1996) Anhedonia and negative symptomatology in chronic schizophrenia. Comprehensive Psychiatry, 37, 5-11.
19. McGlashan TH and Carpenter WT (1976) Postpsychotic depression in schizophrenia. Archives of General Psychiatry, 33, 231-239.
20. Salokangas RKR, Saarijärvi, S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, Tuominen J, Ahola V and Syvälahti E (1996) Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatrica Scandinavica, 94, 175-180.
21. Silver H and Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biological Psychiatry, 31, 698-704.
22. Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di Rosa AE and Caputi AP (1994) Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. International Clinical Psychopharmacology, 9, 281-285.
23. Syvälahti EKG, Kallioniemi H and Lehto H (1994) Citalopram in patients with unsatisfactory response to neuropleptics: an open follow-up study. Methods and Findings of Clinical Pharmacology, 16, 49-55.
24. Taiminen T (1994) Depression among schizophrenic patients - a selective review. Psychiatria Fennica, 25, 185-194.
25. Taiminen TJ and Kujari H (1994) Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. Acta Psychiatrica Scandinavica, 90, 247-251.
26. Taiminen T, Syvälahti E, Saarijärvi S, Niemi H, Lehto H, Ahola V and Salokangas RKR (1996) Prediction of positive placebo response among chronic schizophrenic outpatients. Journal of Nervous and Mental Disease, 184, 109-113.
27. Thakore JH, Berti C and Dinan TG (1996) An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiatrica Scandinavica, 94, 194-197.
28. Terao T, Oga T, Nozaki S, Ohta A, Ohtsubo Y, Yamamoto S, Zamami M and Okada M (1995) Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study. Acta Psychiatrica Scandinavica, 92, 220-224.
29. 2 dopamine receptor binding in humans measured with positron emission tomography, Psychopharmacology, 126, 277-280.
30. Vartiainen H, Tiihonen J, Putkonen A, Koponen H, Virkkunen M, Hakola P and Lehto H (1995) Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatrica Scandinavica, 91, 348-351.